X4 Pharmaceuticals (XFOR) Cash from Investing Activities Growth (1y) (2018 - 2026)
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Cash from Investing Activities Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 93.92% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | -1.35% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -627.53% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -38.43% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -46.70% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -103.94% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 25.90% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | -174.44% |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | -104.33% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -104.33% |
| Mar 31, 2026 | 713.51% |
| Dec 31, 2025 | 295.44% |
| Sep 30, 2025 | -79.98% |
| Jun 30, 2025 | -76.14% |
| Mar 31, 2025 | 41.04% |
| Dec 31, 2024 | -78.38% |
| Sep 30, 2024 | -208.88% |
| Jun 30, 2024 | 2,083.25% |
| Mar 31, 2024 | -59,033.33% |
| Dec 31, 2023 | -14,114.71% |
| Sep 30, 2023 | -57,200.00% |
| Jun 30, 2023 | -12,752.63% |
| Mar 31, 2023 | 59.09% |
| Dec 31, 2022 | -161.54% |
| Sep 30, 2022 | 55.00% |
| Jun 30, 2022 | 55.81% |
| Mar 31, 2022 | 95.56% |
| Dec 31, 2021 | 95.70% |
| Sep 30, 2021 | 95.97% |